RT Book, Section
A1 Leavitt, Andrew D.
A1 Price, Erika Leemann
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1184168526
T1 Increased Platelet Destruction
T2 Current Medical Diagnosis & Treatment 2022
YR 2022
FD 2022
PB McGraw-Hill Education
PP New York, NY
SN 9781264269389
LK accessmedicine.mhmedical.com/content.aspx?aid=1184168526
RD 2024/04/19
AB KEY  CLINICAL  UPDATES  IN  INCREASED  PLATELET  DESTRUCTIONThe  role  of  caplacizumab  in  the  treatment  of  thrombotic  thrombocytopenic  purpura  remains  controversial  given  its  high  cost  and  limited  benefit,  despite  its  inclusion  in  2020  guidelines.Careful  monitoring  of  the  ADAMTS-13  activity  and  inhibitor  status  and  use  of  rituximab  can  prevent  dangerous  relapses.